RNS Number : 1997T
Redx Pharma plc
20 June 2024

REDX PHARMA LIMITED

("Redx" or the "Company")

Redx to Present Zamaporvint Phase 2 Data at ESMO GI

Presentation will include data from both monotherapy and anti-PD-1 combination modules in genetically selected MSS mCRC

Data will also be presented from biliary tract cancer and pancreatic cancer modules

Alderley Park, UK, 20 June 2024 Redx Pharma (JPJ:REDX), the clinical-stage, small molecule biotechnology company, announces that Phase 2 data from zamaporvint (RXC004), a Porcupine inhibitor targeting Wnt-ligand dependent GI cancers, will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress (ESMO GI), 26-29th June, Munich, Germany.

Zamaporvint is a potent, selective, orally-active Porcupine inhibitor in development for hard-to-treat GI cancers. The principal efficacy hypothesis for zamaporvint is for use in combination, which has been investigated in Phase 2 signal searching patient cohorts with anti-PD-1 therapy. Monotherapy for single agent activity has also been investigated. The PORCUPINE study was in genetically-selected patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) as monotherapy and immuno-oncology combination (clinicaltrials.gov NCT04907539). The PORUPINE2 study was in all-comers biliary tract cancer as monotherapy and immuno-oncology combination, and in genetically selected pancreatic cancer as monotherapy (clinicaltrials.gov NCT04907851).

The data will be presented in two posters, one on the PORCUPINE study and one on the PORCUPINE2 study. Notably, these data demonstrate that zamaporvint, in combination with an anti-PD-1 agent in genetically-selected patient populations has the potential to improve upon efficacy outcomes achieved with standard of care alone.

Details of the poster presentations are as follows:

1)

Abstract Title:	Phase 2 results of the Porcupine (PORCN) inhibitor zamaporvint (RXC004) in genetically selected microsatellite stable colorectal cancer patients
Session Title:	Poster Session
Date/Time:	Thursday 27 June 3:35 - 4:30pm CEST
Poster Number:	37P

2)

Abstract Title:	Phase 2 results of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with pancreatic and biliary tract cancer
Session Title:	Poster Session
Date/Time:	Thursday 27 June 3:35 - 4:30pm CEST
Poster Number:	391P

A copy of the posters will be made available on Company's website following the presentation at: https://www.redxpharma.com/scientific-publications/.

For further information, please contact:

Redx Pharma Limited T: +44 (0)1625 469 918

UK Headquarters

Caitlin Pearson, Head of Communications

ir@redxpharma.com

FTI Consulting T: +44 (0)203 727 1000

Simon Conway/ Ciara Martin

About Redx Pharma Limited
Redx Pharma (JPJ: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and cancer-associated fibrosis. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company is currently progressing an industry-leading ROCK inhibitor portfolio through the clinic, including zelasudil, a selective ROCK2 inhibitor for the treatment of interstitial lung diseases including idiopathic pulmonary fibrosis and RXC008, a GI-targeted pan-ROCK inhibitor for the treatment of fibrostenotic Crohns disease. Additionally, the Company has a Phase 2 precision oncology programme, zamaporvint, which it intends to partner for further development.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. To date, six Redx discovered molecules have been progressed into the clinic with the Company's accomplishments evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.

END

NRAZBLBLZQLZBBV